Amicogen, Inc.

Amicogen, Inc. is a South Korea-based biotechnology firm that specializes in developing industrial and pharmaceutical-grade specialty enzymes through its proprietary gene evolution technology, i DNA evolution™. Amicogen, Inc. was founded in 2011 in Gyeongsangnam-do, South Korea, focusing on the biotechnology industry, specifically in enzyme development.

The company's strategy has remained consistent, concentrating on enhancing biotechnological applications without notable pivots. The firm operates independently without any known parent or subsidiary organizations, indicating a self-sufficient operational structure. The founder's history is not documented, nor is any information about previous ventures available. The company has successfully raised funding, with the latest round contributing to its overall financial growth.

Amicogen specializes in advanced biotechnology products, focusing primarily on industrial and pharmaceutical-grade specialty enzymes developed through its proprietary gene evolution technology, i DNA evolution™. These enzymes serve as critical components in the production of biobased materials, protein purification resins, and health-functional food ingredients. Amicogen's offerings are aimed at enhancing human health and promoting sustainable practices within diverse industries. The company's customer base includes businesses across the pharmaceutical, dietary supplement, and cosmetic sectors, as well as research institutions that utilize these enzymes in their processes.

Geographically, Amicogen's products are marketed in several international markets, expanding its reach across Asia, Europe, and North America, thereby catering to a global clientele seeking innovative biotechnological solutions. Amicogen's revenue model is centered around business-to-business transactions, focusing on supplying specialty enzymes and health-related products to various sectors. In 2024, the company's revenue amounted to USD 127. 37 mn, with an EBITDA of USD 10.

24 mn. The company engages in partnerships and direct sales with pharmaceutical manufacturers, healthcare companies, and nutritional product developers. The transactional structure involves bulk orders for Amicogen's enzyme products, which can be integrated into clients' manufacturing processes or used in research applications. Furthermore, Amicogen emphasizes long-term collaborations, often creating tailored solutions that meet specific client needs, enhancing customer loyalty and fostering recurring revenue streams.